ADC Therapeutics Ltd ((ADCT)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ADC Therapeutics Ltd is conducting a Phase 1b clinical study titled ‘A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)’. The primary goal is to assess the safety and tolerability of loncastuximab tesirine when combined with other anti-cancer drugs, and to determine the maximum tolerated dose or recommended dose for expansion.
The study tests combinations of loncastuximab tesirine with polatuzumab vedotin, glofitamab, or mosunetuzumab, all administered as intravenous infusions, with the aim of treating relapsed or refractory B-cell Non-Hodgkin Lymphoma.
This interventional study is non-randomized and follows a sequential intervention model with no masking, focusing primarily on treatment. It is designed to explore dose escalation followed by dose expansion based on initial results.
The study began on July 12, 2021, with its primary completion and estimated completion dates not specified. The latest update was submitted on October 24, 2025, indicating ongoing recruitment and progress.
This update could positively influence ADC Therapeutics’ stock, as successful outcomes may enhance their competitive position in the oncology market. Investors should watch for further developments, especially in comparison to competitors in the B-cell Non-Hodgkin Lymphoma treatment space.
The study is currently recruiting, with more details available on the ClinicalTrials portal.